Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Begins Clinical Trials of ATTR, Hypercholesterolemia Drugs


NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it has initiated two new clinical trials, a Phase III study of its TTR-mediated amyloidosis (ATTR) drug revusiran and a Phase I study of its hypercholesterolemia therapy ALN-PCSsc.

Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.

ATTR is a condition characterized by the accumulation of amyloid deposits in tissues due to mutations in the TTR gene. Revusiran is designed to silence both mutant and wild-type TTR.

The Phase III trial will test revusiran in up to 200 ATTR patients with a manifestation of the disease called familial amyloidotic cardiomyopathy. Primary endpoints of the study are changes in a measurement of how far patients walk over a six-minute period and the reduction in TTR burden between treated and placebo-controlled patients after 18 months.

ALN-PCSsc is designed to silence proprotein convertase subtilisn/kexin type 9, or PCSK9, which has been shown to regulate low-density lipoprotein receptor levels and play a role in plasma low-density lipoprotein clearance.

The study will test single ascending and multiple doses of ALN-PCSsc in up to 76 healthy volunteers.

ALN-PCSsc is being developed in collaboration with The Medicines Company. Initiation of the trial triggered a $10 million milestone payment to Alnylam.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.